Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 27, 2007

Source MDx Inks Translational Medicine Deal with Pfizer

  • Source MDx and Pfizer entered into a multiyear collaboration to develop biomarkers within Pfizer's cancer and inflammation development programs. Additionally, validation of candidate biomarkers will lead to joint commercial opportunities in companion diagnostics.

    This molecular diagnostics partnership will combine Pfizer's experience in genomic profiling with Source MDx' expertise in RNA transcription profiling. The companies will work together on clinical studies to identify RNA-based pharmacodynamic and predictive biomarkers in whole blood and circulating rare cells. The goal is to establish molecular profiles of response and resistance for cancer and inflammation drugs.

    Source MDx will receive an equity investment and a technology license fee plus R&D funding over the term of the alliance. The firm will retain commercial rights to diagnostic biomarkers discovered through this agreement. Pfizer and Source MDx may commercialize any companion diagnostics that are developed as part of the collaboration.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »